Last reviewed · How we verify
AC2592
AC2592 is a small molecule inhibitor of the PI3K delta subunit.
AC2592 is a small molecule inhibitor of the PI3K delta subunit. Used for Treatment of relapsed or refractory follicular lymphoma.
At a glance
| Generic name | AC2592 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PI3K delta subunit, AC2592 is thought to modulate immune cell function and potentially treat various diseases. This mechanism is being explored in the context of AC2592's development for the treatment of certain types of cancer.
Approved indications
- Treatment of relapsed or refractory follicular lymphoma
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |